MedTrace Logo

Atrial Fibrillation and Characterization of Blood Platelet

NCT02817815 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2022-02-28

No results posted yet for this study

Summary

Arterial thromboembolism constitutes a major risk of atrial fibrillation (AF) requiring antithrombotic therapy. Platelets and microparticles (MPs) are important for hemostasis and thrombosis, their role during AF is not well known. The principal objective of this study is to compare morphologic, functional and proteomics characteristics of blood platelet between AF patients and healthy volunteers.

Conditions

Interventions

DEVICE

Electrocardiogram (ECG)

BIOLOGICAL

Blood sampling from the cephalic vein

BIOLOGICAL

Blood sampling from the femoral vein

Blood sampling will be done during radiofrequency ablation of AF procedure, after the introduction of catheter

BIOLOGICAL

First blood sampling from left atrium

Blood sampling will be done during radiofrequency ablation of AF procedure, after transeptal punction

PROCEDURE

Atrial stimulation

Patients will receive atrial stimulation with the catheter positioned in the coronary sinus to induce AF

BIOLOGICAL

Second blood sampling from left atrium

After 20min of continuous AF, a blood sampling from left atrium will be done

Sponsors & Collaborators

  • University Hospital, Bordeaux

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-02
Primary Completion
2018-10-26
Completion
2018-10-26

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02817815 on ClinicalTrials.gov